Kaplan-Meier analysis of the imaging and clinical parameters of PFS (n = 38)
| Parameters | Threshold Values | Median Survival (mo) (95% CI) | ||
|---|---|---|---|---|
| Above Threshold or Presence | Below Threshold or Absence | P Value | ||
| Age (yr) | >60 | 33.47 (1.77–12.27) | 4.57 (3.37–11.63) | .958 |
| Sex | F 3.37 (1.37–4.73) | M 6.17 (3.47–12.27) | .100 | |
| Time to metastasis | ≤229 | 12.27 (3.37–15.00) | 3.50 (2.53–4.73) | .036 |
| KPS | ≤60 | 11.63 (3.67–13.57) | 3.37 (1.37–4.73) | .036 |
| Presence of brain metastasis | 3.50 (3.00–4.97) | 12.27 (4.57–15.88) | .275 | |
| No. of brain metastases | >4 | 3.47 (1.77–11.63) | 4.73 (3.67–12.27) | .701 |
| Presence of extracranial metastasis | 3.47 (2.20–11.63) | 4.57 (3.37–13.57) | .227 | |
| Presence of hydrocephalus | 3.47 (2.57–5.37) | 4.57 (3.10–6.17) | .607 | |
| LC grade | 3.47 (1.13–4.97) | 4.87 (3.67–12.27) | .449 | |
| Enhancement pattern | L 4.17 (2.20–6.17) | N 4.97 (3.00–15.00) | .279 | |
| Combination of LC grade and pattern | 1.77 (1.07–3.50) | 4.87 (3.47–12.27) | .009 | |
Note:—F indicated female patients; M, male patients; L, indicates linear enhancement pattern; N, nodular enhancement pattern.